{"filings":[{"id":93448,"accession_number":"0001193125-26-211863","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon Q1 net loss $44.1M ($0.23/sh); cash $225M; GA Ph3 data Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $44.1M (-$0.23/sh) vs $54.4M (-$0.37/sh) Q1 2025; R&D $35.8M, G&A $10.3M.","Cash $225M as of March 31, 2026; expected runway into H2 2027.","Topline Phase 3 ARCHER II data for vonaprument in GA expected Q4 2026.","Tanruprubart MAA under EMA review; BLA submission with FORWARD data planned 2026.","ANX1502 proof-of-concept data in CAD anticipated in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105071,"accession_number":"0001193125-26-131746","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon reports Q4 and FY2025 net loss of $48.3M and $208.5M; cash $238.3M; vonaprument Phase 3 data due Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2025 $48.3M ($0.28/sh) and FY2025 $208.5M ($1.34/sh); FY2024 net loss was $138.2M.","Cash, equivalents and short-term investments $238.3M at Dec 31, 2025; funds operations into H2 2027.","R&D expenses $184.7M for FY2025, up from $119.4M due to Phase 3 ARCHER II and regulatory filings.","Vonaprument Phase 3 ARCHER II topline data in geographic atrophy expected Q4 2026; enrollment completed July 2025.","Tanruprubart MAA filed in EU for GBS; U.S. BLA submission planned in 2026 based on FORWARD study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105070,"accession_number":"0001193125-26-054695","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chairman Thomas G. Wiggans to retire from Annexon board at 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mr. Wiggans notified the Board on Feb 12, 2026 of his intent to retire and not stand for reelection.","His term as director will end at the 2026 annual meeting; he remains Chairman and committee member until then.","Resignation is not the result of any disagreement with the Company on operations, policies, or strategy.","Mr. Wiggans served on the Board for eight years; management and Board expressed gratitude."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105069,"accession_number":"0001193125-26-012918","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Annexon furnishes updated corporate presentation with no specific material changes disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company updated its corporate presentation for use at the 44th Annual J.P. Morgan Healthcare Conference on Jan 14, 2026.","Presentation is furnished as Exhibit 99.1, but the excerpt provided contains no new financial or pipeline data.","No earnings, guidance, or clinical milestones are reported in the furnished materials.","The filing is a routine Regulation FD disclosure with no substantive quantitative updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105068,"accession_number":"0001193125-26-009740","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Annexon outlines 2026 milestones: GBS MAA filed, GA Phase 3 data H2 2026, oral C1 inhibitor data expected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tanruprubart MAA filed in Europe for Guillain-Barré syndrome; U.S. BLA submission with FORWARD data planned in 2026.","Vonaprument Phase 3 ARCHER II topline data for geographic atrophy expected second half of 2026; enrolled 659 patients.","ANX1502 proof-of-concept data in cold agglutinin disease (CAD) anticipated in 2026; oral C1 inhibitor.","Financial position funds operations into late 2027, well past anticipated key milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121318,"accession_number":"0001193125-25-283191","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Annexon closes $86.25M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 25,096,153 shares at $2.60/share and 3,750,000 pre-funded warrants at $2.599 each.","Underwriters' option for 4,326,922 additional shares exercised in full; total gross $86.25M.","Net proceeds of approximately $80.4M after underwriting discounts and expenses.","Offering closed on November 14, 2025; pre-funded warrants exercisable at $0.001 per share.","Goldman Sachs, TD Cowen, and Wells Fargo acted as joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121317,"accession_number":"0001193125-25-274220","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon posts Q3 net loss $54.9M, extends cash runway to late Q1 2027; GBS MAA filing on track for Jan 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $54.9M ($0.37 per share) in Q3 2025, compared to net loss $34.8M ($0.25 per share) in Q3 2024.","R&D expenses $49.7M, up from $30.1M, driven by Phase 3 ARCHER II trial and global GBS regulatory filings.","Cash and equivalents $188.7M as of Sep 30, 2025; operations funded into late Q1 2027 through key milestones.","Tanruprubart (ANX005) GBS MAA submission on track for Jan 2026; FDA discussions on BLA generalizability package ongoing.","Vonaprument (ANX007) Phase 3 ARCHER II trial enrolled 659 GA patients; topline data expected second half 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137973,"accession_number":"0000950170-25-108859","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon Q2 net loss $49.2M; tanruprubart MAA submission Q1 2026, ARCHER II topline H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $49.2M ($0.34/share) in Q2 2025 vs $29.6M ($0.23) in Q2 2024; R&D $44.2M.","Cash and equivalents $227.0M as of June 30, 2025; runway into Q4 2026.","Tanruprubart MAA for GBS submission expected Q1 2026; FDA BLA discussions ongoing.","Vonaprument ARCHER II Phase 3 enrollment completed (659 patients); topline data H2 2026.","ANX1502 oral C1s inhibitor POC trial update in CAD anticipated by year-end 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155360,"accession_number":"0001193125-25-147005","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["3.03","9.01"],"status":"ready","headline":"Annexon extends 2022 common warrants to June 2026, cash exercise only at $5.806875","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrants exercisable for up to 6,877,622 shares of common stock.","Term extended by one year to June 30, 2026; cash exercise only at $5.806875/share.","Potential aggregate proceeds of up to $39.9 million if all warrants exercised.","Amendment entered with certain holders of the 2022 common stock purchase warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155359,"accession_number":"0001193125-25-137810","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Annexon stockholders elect Class II directors and ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class II directors Jung E. Choi and William D. Waddill elected with 83,207,282 and 62,741,842 votes for, respectively.","Ratification of KPMG as independent auditor for FY2025 passed with 98,033,809 votes for, 124,245 against.","Advisory vote on named executive officer compensation approved with 79,754,521 for, 3,796,829 against, 3,296,805 abstentions.","Broker non-votes totaled 11,334,985 on director elections and advisory compensation vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155358,"accession_number":"0000950170-25-069156","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon Q1 net loss $54.4M; cash $263.7M; GBS, GA programs advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $54.4M ($0.37/share) vs $25.2M ($0.21/share) in Q1 2024; R&D expense $48.2M, up from $21.0M.","Cash and short-term investments $263.7M; runway into H2 2026.","FDA meeting for tanruprubart (ANX005) in GBS scheduled Q2 2025; open-label FORWARD study starting Q2 2025; BLA submission planned.","Phase 3 ARCHER II for ANX007 in dry AMD with GA enrollment completion expected Q3 2025; top line data H2 2026.","Proof-of-concept trial for oral C1s inhibitor ANX1502 in cold agglutinin disease anticipated completion mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173875,"accession_number":"0000950170-25-030824","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon reports Q4 2024 net loss $48.6M; cash $312M; key pipeline milestones for GBS and dry AMD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $312.0M as of Dec 31, 2024; runway into 2H 2026.","Net loss $48.6M Q4 2024 vs $27.9M Q4 2023; R&D expense $43.4M.","Pre-BLA meeting for GBS drug ANX005 targeted 1H 2025; BLA submission planned.","Global registration path for ANX007 in dry AMD with GA; Phase 3 ARCHER II data expected 2H 2026.","ANX1502 oral C1s inhibitor POC trial ongoing; dataset in up to 7 CAD patients expected mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173874,"accession_number":"0001193125-25-005009","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Annexon provides 2025 outlook; targets BLA submission for ANX005 in GBS in 1H 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ANX005 for GBS: Phase 3 showed rapid muscle strength improvement vs placebo; BLA submission targeted for 1H 2025.","ANX007 for GA: Phase 3 ARCHER II enrollment on track for completion in 2H 2025; data expected 2H 2026.","ANX1502 oral C1s inhibitor: clinical proof-of-concept data in CAD expected in 1Q 2025.","Cash runway sufficient into 2H 2026 to achieve key milestones.","Positive Phase 2 ARCHER data for ANX007 showed significant vision preservation on BCVA and LLVA endpoints."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173873,"accession_number":"0001193125-25-004133","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Annexon appoints commercial executive William 'BJ' Jones to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William 'BJ' Jones appointed to Board as Class I director effective Jan 9, 2025, term through 2027 annual meeting.","Receives $40K annual retainer, initial 88K-share option (3-yr monthly vest), and 44K-share annual option.","Jones brings 30 years commercial launch experience; currently CCO at NewAmsterdam Pharma; previously at Biohaven (acquired by Pfizer for $11.6B).","Company notes his expertise valuable as ANX005 (Guillain-Barré Syndrome) and ANX007 (geographic atrophy) approach commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190845,"accession_number":"0001193125-24-279038","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Annexon positive real-world evidence study of ANX005 in Guillain-Barré Syndrome shows benefit over IVIg/PE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ANX005 30 mg/kg showed faster improvement in muscle strength vs matched IVIg/PE cohort at week 1 (p<0.0001).","Patients on ANX005 ~2x more likely to be in better health on GBS-Disability Scale at week 8 (p=0.0459).","Fewer ANX005 patients required mechanical ventilation (15/79 vs 32/79, p=0.022); 12 fewer median days on ventilation and in ICU.","Planned U.S. Biologics License Application submission for ANX005 in GBS in first half 2025.","Study used propensity-score matching between Phase 3 patients (n=79) and IGOS global registry patients (n=79)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190844,"accession_number":"0000950170-24-127027","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon Q3 net loss $34.8M; cash $340M; ANX005 BLA on track for H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $34.8M ($0.25/share) vs $32.5M ($0.43) in Q3 2023.","Cash and investments $340.1M, expected to fund operations into H2 2026.","R&D expenses rose to $30.1M from $27.9M, driven by GBS, GA, and ANX1502 programs.","ANX005 GBS: topline RWE comparability data expected year-end 2024; BLA submission targeted H1 2025.","Strengthened commercial and medical affairs leadership with three senior appointments."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190843,"accession_number":"0001193125-24-240585","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Annexon reports Phase 2 ANX007 data: 0% vision loss in less advanced GA vs 17% sham","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ANX007 monthly-treated patients with less advanced dry AMD lost 0% (0/56) 15+ letters vs 17% (10/59) sham (p=0.0013).","In overall Phase 2 ARCHER, ANX007 monthly reduced 15+ letter loss to 6% (5/89) vs 21% (19/89) sham (p=0.0021).","ANX007 showed 61% decrease in EZ loss in patients with <80% EZ intact at baseline (p=0.0575).","Pivotal Phase 3 ARCHER II data expected in second half 2026.","ANX007 is a first-in-kind Fab targeting C1q intravitreally; data presented at AAO 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207324,"accession_number":"0000950170-24-095073","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon Q2 2024 net loss narrowed to $29.6M; cash $368.7M, runway into H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $29.6M ($0.23/shr) vs. $35.2M ($0.47/shr) in Q2 2023.","Cash, equivalents and short-term investments $368.7M as of June 30, 2024; runway into H2 2026.","ANX005 (GBS) Phase 3 met endpoints; RWE topline data expected year-end 2024; BLA filing H1 2025.","ANX007 (GA) Phase 3 ARCHER II trial dosing initiated; topline data expected H2 2026.","ANX1502 oral C1s inhibitor bridging study to tablet completed; POC data in CAD expected Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207323,"accession_number":"0001193125-24-193404","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Annexon initiates Phase 3 ARCHER II GA trial; Phase 2 data show vision protection","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dosing started in global pivotal Phase 3 ARCHER II trial of ANX007 for geographic atrophy (GA).","Topline data expected in second half of 2026; trial to enroll ~630 patients.","Phase 2 ARCHER: ANX007 reduced ≥15-letter BCVA loss to 5.6% vs sham 21.3% (p=0.0021).","Structural protection: up to 60% photoreceptor preservation in central fovea (p=0.0319).","FDA/EMA aligned on BCVA as primary endpoint; EU PRIME and US Fast Track designations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224731,"accession_number":"0001193125-24-167962","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Annexon Phase 3 trial of ANX005 meets primary endpoint; GBS patients recover faster","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint at Week 8: 2.41-fold higher likelihood of better health state (p=0.0058).","ANX005 patients walked 31 days earlier and came off ventilation 28 days earlier vs placebo.","At Week 26, 21.5% of ANX005 patients fully recovered (GBS-DS=0) vs 8.6% on placebo (OR 4.14, p=0.0092).","Subgroup with North American/European baseline characteristics showed 3x greater likelihood of better health state at Week 8.","Single infusion generally well-tolerated; safety profile similar to placebo, no increased infections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224730,"accession_number":"0001193125-24-159748","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Annexon stockholders elect Class I directors, ratify KPMG, and approve say-on-pay at 2024 Annual Meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected William H. Carson, M.D. (78,919,065 for, 597,431 withheld) and Muneer A. Satter (60,965,423 for, 18,551,073 withheld) as Class I directors.","Ratified KPMG LLP as independent auditor for fiscal 2024 with 84,114,097 for, 36,225 against, 8,491 abstain.","Advisory vote on named executive officer compensation approved: 77,548,918 for, 1,895,328 against, 72,250 abstain.","Broker non-votes were 4,642,317 for director election and say-on-pay; no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224729,"accession_number":"0001193125-24-157454","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Annexon prices $125M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 13,001,120 shares at $6.25/sh and 7M pre-funded warrants at $6.249/sh; gross proceeds $125M.","Net proceeds expected ~$116.9M after underwriting discounts and expenses; offering closed June 7, 2024.","Underwriters granted 30-day option to purchase up to 3,000,168 additional shares.","J.P. Morgan, Jefferies, TD Cowen, BofA Securities and Wells Fargo Securities served as joint book-running managers.","Funds will support development of classical complement-mediated neuroinflammatory therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224728,"accession_number":"0001193125-24-153625","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Annexon Phase 3 GBS trial meets primary endpoint; ANX005 shows 2.4-fold improvement on GBS-DS at week 8","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 trial met primary endpoint: single infusion of ANX005 30 mg/kg achieved 2.4-fold improvement on GBS-DS at week 8 (p=0.0058).","Key secondary endpoints met: 28 fewer days on ventilation (p=0.0356), 31-day reduction in time to walk independently (p=0.0211), and early muscle strength gains.","ANX005 was generally well-tolerated; most adverse events mild-to-moderate, no drug-related deaths or serious infections.","RWE comparability protocol initiated with IGOS; BLA submission and RWE data expected first half 2025.","GBS affects >22,000 hospitalized annually in U.S./Europe; no FDA-approved treatments currently."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224727,"accession_number":"0000950170-24-058629","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon Q1 net loss $25.2M; cash $264.9M; Phase 3 GBS data due Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.2M ($0.21/share) vs $38.7M ($0.52) in Q1 2023; R&D spend $21M vs $32.3M.","Cash, equivalents & short-term investments $264.9M as of March 31, 2024, runway into mid-2026.","Topline Phase 3 data for ANX005 in Guillain-Barré Syndrome expected Q2 2024.","Pivotal Phase 3 ARCHER II trial for ANX007 in geographic atrophy to start mid-2024; ARROW head-to-head vs SYFOVRE planned H2 2024.","Proof-of-concept data for oral ANX1502 in cold agglutinin disease on track for H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224726,"accession_number":"0001193125-24-133086","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Annexon presents positive Phase 2 data for ANX007 in GA; plans Phase 3 trials in 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ANX007 showed 73% relative risk reduction in BCVA 15-letter loss at 12 months in Phase 2 ARCHER trial.","Statistically significant slowing of low luminance visual acuity loss and reduction in photoreceptor loss observed.","No choroidal neovascularization increase and no cases of vasculitis; generally well-tolerated safety profile.","Global pivotal Phase 3 ARCHER II (vs sham) expected mid-2024; Phase 3 ARROW (vs SYFOVRE) expected H2 2024.","Preclinical data show C1q blockade protects photoreceptor synapses and preserves retinal function in GA models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243996,"accession_number":"0000950170-24-036399","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon reports Q4 2023 net loss $27.9M; cash $259.7M; Phase 3 GBS data Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2023 $134.2M vs $141.9M in prior year; R&D spend $113.8M.","Cash and short-term investments $259.7M as of Dec 31, 2023; runway into mid-2026.","Phase 3 ANX005 GBS topline data expected Q2 2024; BLA submission supported by RWE from IGOS.","Phase 3 ANX007 GA ARCHER II trial (sham-controlled) to initiate mid-2024; ARROW head-to-head vs SYFOVRE planned H2 2024.","Completed $125M financing in December 2023 extending operating runway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}